Vertex, Verve in gene editing partnership for liver disease worth up to $466M
Rasi Bhadramani


Vertex Pharmaceuticals (NASDAQ:VRTX) and Verve Therapeutics (NASDAQ:VERV) will collaborate on developing a gene editing program for a liver disease.
Under the four-year arrangement, Verve (VERV) will be responsible for discovery, research and certain preclinical development of a novel in vivo gene editing program for a target. Vertex will pay for these program costs and also handle further development, manufacturing and commercialization of any program from Verve's (VERV) research.

Verve (VERV) will receive a $60M upfront payment that includes a $35M equity investment. Verve is also eligible for up to $66M in success payments, up to $340M in milestones, and tiered royalties on future net sales.
Verve shares are down 16% in post-market trading after announcing a $200M underwritten stock offering.